Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $1.7 million.

  • Beam Therapeutics' Cash from Financing Activities rose 32.73% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.6 million, marking a year-over-year increase of 1161.96%. This contributed to the annual value of $7.7 million for FY2024, which is 97.20% down from last year.
  • Per Beam Therapeutics' latest filing, its Cash from Financing Activities stood at $1.7 million for Q3 2025, which was up 51.04% from $1.1 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Cash from Financing Activities high stood at $473.4 million for Q1 2025, and its period low was $133,000 during Q2 2024.
  • Over the past 3 years, Beam Therapeutics' median Cash from Financing Activities value was $3.4 million (recorded in 2024), while the average stood at $69.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 341,268.09% in 2021, then plummeted by 99.88% in 2024.
  • Beam Therapeutics' Cash from Financing Activities (Quarterly) stood at $21.5 million in 2021, then skyrocketed by 48.60% to $32.0 million in 2022, then rose by 5.31% to $33.7 million in 2023, then plummeted by 89.78% to $3.4 million in 2024, then soared by 32.73% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.1 million for Q2 2025, and $473.4 million during Q1 2025.